newsfilter
← Earnings
Earnings Releases·

Rockwell Medical — Third Quarter 2026 Earnings Summary

  • Third quarter net sales rose 20% year-over-year to $19.1 million, while gross margin improved to 16% from 14% in the prior period; however, the company reported a net loss of $2.3 million and adjusted EBITDA of ($0.3) million for the quarter.
  • Management announced a transformational acquisition of Vantive's global hemodialysis business, projecting the combined entity will generate annual revenue between $400 million and $450 million.
  • Cash and equivalents decreased to $22.5 million from $24.8 million in June, driven by capital purchases for manufacturing automation and increased accounts receivable, alongside $847,000 in transaction-related expenses.
  • CEO Mark Strobeck cited solid upward momentum and strong customer adoption, positioning the company to capitalize on growth opportunities following the strategic expansion of its product portfolio and global reach.
Company
ROCKWELL MEDICAL INC
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic